Verastem Oncology announced the launch of Let's Talk About LGSOC, a new initiative that calls attention to low-grade serous ovarian cancer (LGSOC). Let's Talk about LGSOC provides detailed information about LGSOC and its symptoms, its differences from the more common high-grade serous ovarian cancer, tips and resources, and ways to connect with others in the LGSOC community. LGSOC is a rare form of ovarian cancer that commonly affects younger women with a median age at diagnosis between 45-551, and for many, the disease and its treatment will have a long-lasting impact on mental and physical health, including fertility and early menopause.

Limited treatment options are available for LGSOC and no treatments specifically for LGSOC have been approved to date. LGSOC has only recently been classified as a separate disease as compared to the more common high grade serous ovarian cancer (HGSOC) with different epidemiology, pathology, clinical presentation and outcomes. LGSOC is primarily driven by the RAS pathway, which is a key regulator of several aspects of normal cell growth and malignant transformation, and present in a third of all cancers, including LGSOC.

LGSOC is a serious disease that is likely to be diagnosed when it has already spread outside of the ovaries. It is relatively resistant to chemotherapy and highly recurrent. Eighty-five% of people with LGSOC will have their cancer come back after remission.

LGSOC represents 6-8% of all ovarian cancers.